Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Neuroendocrine Tumors 7Sarcoma 3Small Cell Lung Carcinoma 2Neoplasms 2Biliary Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × surufatinib × Clear all
NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡